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1. Introduction 
Amyloidosis is a disease characterized by the deposition of abnormal proteins in 
extracellular tissue. The deposits originate from serum derived or locally produced proteins. 
(Sipe et al., 2010) The term “amyloid” was first used by Rudolph Virchow in 1854. (Saleiro et 
al., 2008) According to the Nomenclature Committee of the International Society of 
Amyloidosis 2010 recommendations, an amyloid fibril protein must occur in tissue deposits 
and exhibit affinity for Congo red and green birefringence when viewed by polarization 
microscopy. Furthermore, the protein must have been unambiguously characterized by 
protein sequence analysis (DNA sequencing in the case of familial diseases). In this chapter, 
we will focus on the pulmonary manifestations of amyloid. We will discuss the 
classification, presentation, symptoms, diagnostic testing and therapeutic options with 
regards to amyloid in the respiratory tract. 
Amyloidosis had been classified over the years based on the site of deposition and presence 
or absence of other diseases. (Thompson & Citron, 1983) The term “Generalized” or 
“Systemic” had been used to describe deposition in multiple anatomic sites and “localized” 
used to describe deposition in one anatomic site. The term “secondary” used to describe 
patients with coexistent disease like multiple myeloma and “primary” for patients with no 
such coexistent disease. (Utz et al., 1996) 
2. Classification of pulmonary amyloidosis 
Amyloid in the respiratory tract has been classified by authors at The Mayo Clinic as 
associated with systemic amyloidosis and localized pulmonary disease. (Utz et al., 1996) The 
most common cause of the respiratory amyloid disease is secondary to systemic AL 
Amyloidosis which accounts for up to 80% of pulmonary amyloid. (Pitz et al., 2006) 
Moreover, it has been reported that 88% of patients with systemic amyloid have pulmonary 
disease. (Smith et al., 1979)  
Amyloidosis localized to the respiratory tract was first recognized by Lesser in 1877. (Lesser, 
1877) Amyloidosis at present is best classified by the protein fibrils and then by the location 
of sites involved clinically. To date, there are 27 known extracellular fibril proteins identified 
in humans. Table 1 lists some of the common protein subunits. Clinically there are three 
broad classifications of pulmonary involvement. The amyloid deposition may predominantly 
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involve the tracheobronchial tree with nodules or submucosal infiltration. There can also  
be predominant interstitial localization. A third presentation is with single or multiple 
pulmonary parenchymal nodular deposits. A combination of radiographic and 
bronchoscopic studies provides this classification of pulmonary amyloidosis. Interestingly, 
it is uncommon for interstitial and tracheobronchial involvement to develop in the same 
patient.  
 
Classification 
 
Amyloid 
Protein 
Fibril Type 
Symptoms Imaging Treatment 
Nodular AL Incidental  
Finding 
Cough 
Dyspnea 
Round nodules 
with sharp 
margins, 
subpleural and 
peripheral, may be 
cavitary, can be 
PET avid 
Observation 
Local treatment  
 Bronchoscopic 
 (if in larynx) 
Lobectomy   
 (very rarely) 
Tracheo-
bronchial 
AL, 
Rare AA 
Cough 
Dyspnea 
Hemoptysis 
Tracheal and 
bronchial wall 
thickening, post-
obstructive 
pneumonia, 
atelectasis 
Observation 
Local treatment  
 with laser  
 therapy 
External Beam  
 Radiation 
Surgery (rarely) 
Diffuse 
Alveolar- 
Septal 
AL, AA, 
ATTR 
Cough 
Dyspnea 
Lethargy 
Interlobular septal 
thickening, traction 
bronchiectasis 
Usually requires 
systemic treat- 
ment with  
chemotherapy   
and/or stem  
cell transplant 
Adenopathy AL Incidental  
Finding 
Compression  
of the airway  
Wheezing 
Cough 
Dyspnea 
Extrathoracic 
nodes more 
common, often 
calcify with an 
eggshell or 
popcorn pattern 
Observation 
Bronchoscopic 
(Stenting) 
Surgical (rarely)  
Pleural  
Effusion 
AL Dyspnea, 
cough, 
lethargy 
Opacity on CXR 
Pleural studing on 
CT 
Thoracentesis 
Chest tube  
PleurX catheter 
Chemical or  
Mechanical   
pleurodesis 
Table 1. Classification of Pulmonary Amyloidosis with Commonly Encountered Symptoms, 
Radiographic Findings, and Treatment Modalities 
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2.1 Tracheobronchial amyloidosis 
Pulmonary nodules of amyloid deposits can be found in the larynx, tracheobronchial tree 
and lung parenchyma. Discrete nodular deposits in the larynx were described in 1919 (New, 
1919). Tracheobronchial amyloidosis is characterized by deposits in the trachea and large 
bronchi. This is the most common form of primary pulmonary amyloidosis. (Sugihara et al., 
2006) Isolated tracheal disease is very rare with less than 20 cases reported in the literature 
as of 2006. (Sharma & Katlic, 2006) It typically presents in the fifth and sixth decade of life 
and is slightly more common in females than males. (Berk et al., 2002) As previously 
mentioned, tracheobronchial amyloid deposition can occur in two forms: nodular or 
unifocal disease and diffuse submucosal disease. Tracheobronchial amyloidosis has been 
associated with tracheobronchopathia osteochondroplastica (TBO) by some authors. (Jones 
& Chatterji, 1977) Tracheobronchopathia osteochondroplastica is a disorder characterized by 
the deposition of calcified or cartilaginous submucosal nodules in the airways. (Capizzi et 
al., 2000) The uncertainty is related to the fact that most patients with TBO do not show 
evidence of amyloid deposition. (Mimori et al., 1998)  
In a retrospective review of a series at The Mayo Clinic of 17 patients with biopsy proven 
tracheobronchial amyloidosis concluded that this form of pulmonary amyloid appeared to 
be a type of localized amyloid, with protein fibril deposition only present in the 
tracheobronchial tree. (Utz et al., 1996) This form is quite rare with less than 150 cases 
published in the medical literature. Although tracheobronchial amyloidosis often follows a 
relatively stable course, it can present with significant morbidity in patients with extensive 
airway involvement. It may require repeated therapeutic bronchoscopies in an attempt to 
prevent progression of airway involvement. Three patterns of airway involvement have 
been described by Berk et al: (1) proximal, (2) mid or main bronchial, and (3) distal disease. 
(Berk et al., 2002) Although tracheobronchial amyloidosis is most commonly caused by the 
AL form of amyloid fibril deposition, AA amyloidosis has also been reported in a case of 
tracheobronchial amyloidosis complicating mediastinal fibrosis. (Hoag & Yung, 2008)  
2.2 Diffuse interstitial amyloid 
Diffuse amyloid deposition in the lung parenchyma is usually associated with systemic AL 
amyloidosis. It is characterized by widespread amyloid deposition involving small vessels 
and the interstitium. There is little association between the extent of amyloid deposition in 
the lung and level of functional compromise. A Mayo clinic series included 35 patients who 
had pulmonary involvement with primary systemic amyloidosis. Celli and coauthors 
reported case series of 12 patients with AL lung disease, of which only 1 patient his clinical 
outcome dictated by his pulmonary involvement. (Celli, 1978) Cordier and colleagues 
reported that only 10% of patient deaths were due to AL lung disease in their series. 
(Cordier, 1986) Pathologists at John Hopkins have examined the association between cardiac 
and pulmonary amyloid. (Smith et al., 1979) They found that all patients with pulmonary 
amyloid deposition had cardiac amyloid disease. They concluded that histologic and clinical 
pulmonary disease in AL patients was principally a marker of severe cardiac infiltration.  
2.3 Nodular amyloidosis  
Amyloid nodules in the lung parenchyma are usually incidental findings on chest 
radiographs and usually need to be differentiated from neoplastic lesions. These nodules are 
typically located peripherally or subpleurally, and they can also be bilateral in some cases. If 
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these lesions are located more centrally, airflow limitation may occur leading to 
symptomatic presentations. Moreover, these amyloid lesions may cavitate. (Cordier et al., 
1986) AL amyloidosis is a well recognized complication of Sjogren’s syndrome and is most 
often associated with localized nodular pulmonary amyloidosis. An association with benign 
hypergammaglobulinemic purpura has been reported in one patient. (Bignold et al., 1980) 
3. Other manifestations of thoracic amyloidosis 
3.1 Adenopathy 
Hilar and mediastinal adenopathy are commonly associated with the AL form of systemic 
amyloidosis, and rarely adenopathy is present in localized pulmonary disease. (Lachmann 
& Hawkins, 2006) The majority of patients with amyloid-associated lymphadenopathy have 
detectable circulating monoclonal immunoglobulin which are typically associated with very 
low grade lymphoplasmacytic lymphoma or Waldenstrom‘s macroglobulinemia. (Plockinger 
et al., 1993) Plockinger et al. reported a case of nodular amyloidosis of hilar lymph nodes 
with no evidence of a paraprotein immunoglobulins or light chains present on 
immunoelectrophoretic analyses of the plasma and urine. Amyloid infiltrated nodes 
frequently calcify in a “popcorn” pattern or an “eggshell” conformation. (Gross, 1981)  
3.2 Pleural effusions 
Pleural effusions have also been reported in patients with systemic amyloid disease. The 
incidence of pleural effusion in amyloidosis is not known. Effusions can be unilateral or 
bilateral, and they can present with either exudative or transudative chemistries. (Berk et al., 
2003) One of the first reports of amyloid-associated pleural effusion included five patients 
by Kavuru and colleagues. (Kavuru et al., 1990) These authors found that pleural effusions 
in the majority of their patients (60%in their series) were believed related to either 
congestive heart disease or nephrotic syndrome, and only 40% of pleural effusions were 
“idiopathic”. Despite this they found that even those patients with transudative effusions 
had pleural infiltration with amyloid on biopsy. The Amyloid Program at Boston University 
reported their 7 year experience with 636 patients. (Berk et al., 2003) Thirty five patients in 
this series (6%) had large recurrent pleural effusions along with another 10-15% with less 
significant effusions. They compared patients with primary systemic amyloidosis and 
coincident cardiomyopathy without pleural effusions and patients with recurrent large 
pleural effusions. They noted exudative chemistries in pleural fluid of 37% of their patients 
along with chylothorax in another two patients. In contrast to the conclusions drawn by 
Kavuru et al., their hypothesis was that direct amyloid infiltration of the parietal pleural was 
responsible for large recurrent pleural effusions. Their claim was supported by 
thoracoscopic descriptions of pleural studding and histologic evidence of amyloid 
infiltrating pleural surfaces on biopsy. (Kavuru et al., 1990) After extensive comparisons 
between the two groups using echocardiography, they concluded that cardiac dysfunction 
alone was not sufficient to produce the pleural effusions in their cohort. The paucity of 
chylous effusions in patients with AL amyloid despite the propensity of mediastinal 
lymphadenopathy points towards direct amyloid infiltration of lymph nodes by amyloid as 
the cause of chylothorax as opposed to a compression of lymph nodes. Although 
uncommon, pleural effusions in patients with primary pulmonary amyloidosis can be 
hemorrhagic. (BoydKing et al., 2009) 
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4. The clinical presentation of pulmonary amyloidosis 
Pulmonary amyloid may present with symptoms or may be found as an incidental finding 
on thoracic imaging. Patients present to pulmonologists in a number of ways: patients with 
systemic amyloidosis may present with respiratory symptoms; localized forms of amyloid 
may be detected incidentally on imaging or biopsy; and patients may present with 
respiratory symptoms that warrant pulmonary workup leading to the diagnosis of 
amyloidosis. (Lachmann & Hawkins, 2006; Sipe et al., 2010; Thompson & Citron, 1983) 
Tracheobronchial amyloidosis usually presents in fifth decade of life with symptoms of 
cough, dyspnea, wheezing, and hemoptysis. (Berk et al., 2002) In addition, hoarseness is 
frequently reported.  
The most common symptoms of amyloid involvement with the respiratory system are 
cough, wheezing, dyspnea on exertion, and hemoptysis; none of which are uniquely specific 
to the diagnosis of pulmonary amyloidosis. One elderly male presented with diffuse 
alveolar hemorrhage. (Shenin et al., 2010) Amyloid nodules in the lung parenchyma are 
most often asymptomatic and are usually incidental findings on imaging studies; however, 
they sometimes can produce space occupying effects, most often if they limit either air or 
blood flow in the lungs. These nodules tend to calcify, and sometimes they may cavitate. 
They can cause lumenal narrowing of the airways and thus may lead to post obstructive 
atelectasis and/or pneumonia. Diffuse alveolar-septal amyloidosis related to systemic AL 
disease may present with symptoms of dyspnea or even more frightening symptoms of 
hemoptysis due to dissection of pulmonary arteries infiltrated by amyloid protein deposits 
(Cools et al., 1996; Road et al., 1985) or massive pulmonary embolism related to thrombosis 
of inferior vena cava. Mediastinal or hilar adenopathy is less common than extrathoracic 
adenopathy in patients with systemic AL disease. However, these patients may sometimes 
present with cervical nodes that may enlarge, become tender or recede in periods mimicking 
sarcoidosis. Pleural effusions in patients with amyloidosis will cause dyspnea and may at 
times require repeated thoracenteses to relieve symptoms.  
5. Diagnosis of pulmonary amyloid 
5.1 General considerations for diagnosis 
When systemic amyloid disease is present, consideration for pulmonary evaluation for 
amyloid involvement should be based upon symptoms and clinical suspicion. The delay 
from time of presentation to the diagnosis of pulmonary involvement has been up to 17 
months in some series. (O’Regan et al., 2000) In a patient with systemic amyloidosis, exercise 
limitation or cough should prompt an evaluation for lung involvement. In the setting of 
isolated pulmonary disease, amyloid is often low on the differential diagnosis. Pulmonary 
amyloidosis can be evaluated with plain films, computed tomography, bronchoscopy and 
pulmonary function testing. Figure 1 depicts an algorithm of a diagnostic approach for 
patients with systemic amyloidosis.  
5.2 Radiographic evaluation 
As previously described, the nodular form amyloidosis is most often an incidental finding 
on thoracic imaging. The plain chest radiograph can be normal in as many as half of patients 
with pulmonary nodular amyloidosis. (O’Regan et al., 2000) Amyloid nodules are generally 
described as rounded with sharp, discreet margins, and they are occasionally cavitary  
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Diagnosis of Amyloidosis
      Pathologic and
Immunohistochemical
            analysis
 Confirmation with Congo
Redstaining and polarizing
              microscopy
Systemic or Localized
            Disease
    Localized to
Respiratory Tract
Systemic
 Disease
●Chest Radiography
●Computed Tomography
●Pulmonary Function Testing
●Bronchoscopy
●     I-SAP scintigraphy
●24 hr urinaryprotein
●Liver Function Testing
●Electrocardiogram
●Echocardiogram
Observation
     Localized Treatment
●Bronchoscopic
●External Beam Radiation
Chamotherapy Stem Cell Transplantation
        +Chemothrerapy
Systemic Therapy
123
 
Fig. 1. Flow diagram of a decision pathway for the evaluation and treatment of respiratory 
amyloidosis 
in appearance. One case report found that a lesion of amyloid measured 282 Hounsfield 
units, which is significantly less dense than blood. (M’Rad et al., 1988) Pulmonary nodular 
amyloidosis are predominantly subpleural and peripheral with a random distribution.  
Imaging of patients with diffuse alveolar-septal disease may show infiltrative opacities on 
chest plain radiographs. In systemic amyloidosis, diffuse interstitial disease is most 
common. This may be reticular nodular on computed tomography imaging. Interlobular 
septal thickening and diffuse irregular lines with some honeycombing can be seen at the 
lung bases peripherally, and traction bronchiectasis can also be seen. Some report that 
diffuse cystic changes may predominate. (Wink, 2003) 
Tracheal and bronchial wall thickening or discrete tumor masses may be a CT finding of 
tracheobronchial amyloid. The presence of multifocal masses with calcification should 
prompt a differential diagnosis of carcinoma, Wegener’s Granulomatosis, relapsing 
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polychondritis, tracheobronchial tuberculosis, pulmonary hyalinizing granuloma, 
tracheobronchopathia osteochondroplastica along with tracheobronchial amyloidosis. 
(Bhadra et al., 2010; Carter & Patchefsky, 1998; Gibbaoui et al., 2004) Circumferential 
calcification involving the membranous airway should suggest amyloidosis as other forms 
of airway thickening do not involve this portion.  
Positron emission tomography (PET) may demonstrate increased uptake of  
18F-flourodeoxyglucose (FDG) in patients with nodular amyloidosis. (Currie et al., 2005; 
Kung et al., 2003; Seo et al., 2010) From the studies of PET with pathology confirming 
amyloidosis, the standardized uptake value (SUV) ranged from 1.8 to 6.81, suggesting the 
need for biopsy to exclude malignancy. Coincident pulmonary nodular amyloid and 
adenocarcinoma has been reported in a patient with systemic AL amyloidosis. (Miyazaki et 
al., 2011) An uncharacteristic speculated appearance of the nodule in question in this case 
highlights the need for careful review of thoracic imaging in conjunction with a high index 
of suspicion. Coincident carcinoma and amyloid deposits have been described in thyroid 
medullary carcinoma. (Westermark et al., 2007)  
5.3 Pulmonary function testing 
Pulmonary function testing (PFT) in patients with pulmonary involvement of amyloidosis is 
similarly variable due to the variety of presentations. Overall, pulmonary functions can be 
normal or exhibit obstructive or restrictive disease. When tracheobronchial amyloidosis is 
present, the most common finding is airflow limitation as demonstrated by a reduced ratio 
of forced expiratory volume in the 1st second (FEV1) to forced vital capacity (FVC) of less 
than 70%. The severity is dependent on the degree and location of amyloid deposition. In as 
series of patients with tracheobronchial amyloidosis from Boston, those with proximal 
disease tended to have more severe airflow limitation than those with more distal disease, 
although both groups had significant air trapping present with elevated residual volumes. 
(O’Regan et al., 2000) With the nodular form of pulmonary amyloidosis, direct compression 
of central airways may lead to obstructive patterns on PFTs. Evidence of a fixed upper 
airway obstruction not only suggests central airway disease but also portends a higher 
probability of progressive central obstructive disease. (Bhadra et al., 2010)  
Restriction may be present as would be expected in patients with significant pleural 
effusion, or in very severe cases of diffuse alveolar-septal disease. Diffusing capacity for 
carbon monoxide is most often preserved. 
5.4 Diagnostic bronchoscopic findings 
The bronchoscopic findings of pulmonary amyloidosis vary with the classification of 
disease. In patients with interstitial or pulmonary nodular disease the endobronchial 
appearance on bronchoscopy may be entirely normal. In contradistinction to the interstitial 
variety, those with tracheobronchial amyloidosis commonly have significant visible 
pathology. The lesions of tracheobronchial amyloid can be nodular, sessile, or polyploidy. 
The sessile lesions have been described as hard yellow plaques that may be expansive or 
thinner longitudinal irregularities. Cobblestoning of the mucosa may be present. The sessile 
lesions may cause significant airway stenosis, and these regions of stenosis can be diffuse.  
The nodules or polypoid lesions may suggest endolumenal carcinoma to both the 
experienced and inexperienced bronchoscopist. These nodules are usually firm, non mobile, 
and covered with hypervascular mucosa. Because of the hypervascularity in conjunction 
with the infiltrated submucosa, the endobronchial lesions in tracheobronchial amyloidosis 
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are quite friable, and bleed easily with minimal bronchoscopic contact. (Hoag & Yung, 2008) 
In contradistinction to tracheobronchopathia osteochondroplastica (TBO), the membranous 
trachea and mainstem airways are not spared. Tracheobronchial amyloidosis was associated 
with TBO in 22% in one series. (Piazza et al., 2003)  
Ultimately, the diagnosis of pulmonary amyloidosis requires histologic confirmation. An 
excellent overview of the pathologic features of pulmonary amyloidosis has been published. 
(Katzenstein, 1997) Congo red staining that produces green birefringence under polarized 
light remains the gold standard for diagnosis. Classic teaching is that these lesions have a 
tendency to bleed. An increased risk of hemorrhage during biopsies of amyloidotic tissues 
may result from increased fragility of involved blood vessels, reduced elasticity of tissues 
and rarely to an acquired deficiency of clotting factors 9 or 10. So while endolumenal forceps 
biopsy is required, preparation for potential airway bleeding is advisable. Strange et al. 
reported on the fatal hemorrhage and air embolism complicating a routine transbronchial 
biopsy of a patient with pulmonary amyloidosis. (Strange et al., 1987) Treatment with low 
level Neodymium: Yttrium Aluminum Garnet (Nd:YAG) laser or argon plasma coagulation 
(APC) can be effective in controlling bleeding from the central airway amyloid lesion. Both 
approaches offer non contact therapy. Application of electrocautery can create rebleeding by 
disruption of the coagulum. The non-contact therapies (APC and Nd:YAG Laser) does not 
disrupt the bleeding site and remove the coagulum created by its application. Pretreatment 
with endobronchial epinephrine injections into the lesions may decrease the bleeding risk. 
Effective biopsy may be obtained by the use of Wang needle or endobronchial forceps. 
Biopsy of the lesions may be difficult due to calcifications, and small biopsy specimens are 
open to sampling errors. False positive results also do occur in routine practice, usually as a 
result of poor Congo red staining. A confirmatory stain with Thioflavine T, which fluoresces 
yellow-green, may be helpful. (Saleiro et al., 2008) Any bronchoscopic finding suggesting 
tracheobronchopathia osteochondroplastica should be stained with Congo red due to the 
similarity of endobronchial appearance. (Bhadra et al., 2010) When the tissue is too calcified 
or when the operator feels uncomfortable with handling larger volume bleeding open 
surgical biopsy may be warranted. 
Like any tumor mass, malignant or non-malignant, post obstructive pneumonia can develop 
in pulmonary amyloidosis. Protected brush samples or clean bronchoalveolar lavage for 
culture should be obtained when there is a high grade stenosis or evidence of mucopurulent 
drainage.  
Once histologic evaluation with Congo red staining has been performed, immunochemistry 
to determine protein fibril type should be performed. Anatomical and functional evaluation 
of the various organs involved in systemic amyloidosis should also be performed. (Hawkins 
et al., 1990) Radiolabeled Serum Amyloid P (SAP) component localizes specifically to 
amyloid deposits in vivo in proportion to the amount of amyloid present and enables 
diagnosis, quantification and monitoring of amyloid to be performed scintigraphically. 
(Hazenberg et al., 2007) 
6. Follow up of the patient with pulmonary amyloid 
Several non-invasive methods of surveilling the progress of disease include computed 
tomography imaging and pulmonary function testing, especially serial spirometry. Proximal 
disease can present as pattern of fixed airway obstruction on flow volume loops, (Lachmann 
et al., 2006) or progression of disease may be apparent with progression flow limitation as 
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demonstrated by decreasing FEV1. Radiographic imaging may show areas of atelectasis or 
hyperinflation due to progression of obstructing endobronchial disease. Due to the relative 
rarity of this condition the most appropriate method of surveillance is not known.  
7. Management of pulmonary amyloidosis 
The outcome of patients with pulmonary amyloidosis reported in the literature is variable. 
From a series of 21 patients with primary pulmonary amyloidosis, the median survival was 
16 months and no patients were alive at five years. (Utz et al., 1996) The survival of this 
cohort was much shorter than would be expected in comparison to patients with systemic 
amyloidosis without pulmonary involvement. As some have suggested that respiratory 
failure is rarely the direct cause of death in patients with amyloidosis, it seems that its 
presence is a marker of more severe disease. In contrast, in another series over 15 years with 
10 patients reported survival averaged 8 years. (O‘Regan et al., 2000) In this series death was 
predominantly caused by respiratory complications.  
Due to the variability of amyloid involvement in the pulmonary system, the treatment for 
respiratory amyloidosis ranges from observation to bronchoscopic or surgical resection 
based on severity and symptomatology. Management decisions are mostly based on an 
individual basis. Systemic amyloidosis can be treated with chemotherapy while localized 
forms are typically treated with local interventions.  
7.1 Chemotherapy  
Infiltrative and systemic disease has been amenable to chemotherapy with oral melphalan 
and prednisone. (Kyle et al., 1997) A prospective study done at The Mayo Clinic in patients 
with systemic amyloidosis showed that combination therapy with melphalan, prednisone 
and colchicine or melphalan and prednisone resulted in prolonged survival compared to 
colchicine alone. The median duration of survival after randomization was 8.5 months in the 
colchicine group, 18 months in the group assigned to melphalan and prednisone, and 17 
months in the group assigned to melphalan, prednisone, and colchicine (p<0.001). 
(Wechalekar et al., 2008) The National Amyloidosis Center in The United Kingdom has 
divided its treatment strategies for systemic AL disease into low dose, intermediate and 
high dose regimens. They recommend one of the intermediate dose regimens involving risk-
adapted CTD (cyclophosphamide, thalidomide and dexamethasone) or oral mel-dex 
(melphalan, dexamethasone) as first line therapy, and autologous stem cell transplantation 
as an alternative treatment. (Cohen et al., 2007) Stem cell transplantation has been attempted 
with variable success in more severe disease. Recent phase 2 trials in systemic amyloidosis 
showed that risk-adapted Stem Cell Transplant with adjuvant thalidomide and 
dexamethasone is feasible and results in low treatment related mortality and high 
hematological and organ response rates in patients. (Cohen et al., 2007) There are several 
ongoing trials at amyloid centers in the United States and internationally, and physicians are 
encouraged to refer their patients to be enrolled in these studies in order to determine best 
practices.  
7.2 Therapeutic bronchoscopy 
In light of poor responses of tracheobronchial amyloid to systemic therapy, the majority of 
these patients will require endobronchial therapy. Bronchoscopic therapies remain the key 
to airway management in these patients. 
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Ablative therapy with Neodymium: Yttrium Aluminum Garnet (Nd:YAG) or Carbon 
Dioxide (CO2) laser has been fairly successful. It appears that amyloid is very sensitive to 
photoablation. (Saleiro et al., 2008) Nd:YAG laser therapy is the most commonly utilized 
and is not only ablative but has significant hemostatic effects which is of particular benefit in 
these friable lesions. Laser ablation is the standard of care for endobronchial amyloidosis. In 
a retrospective series of 32 patients over 19 years, sixteen had persistent asymptomatic 
endolumenal disease. (Piazza et al., 2003) Two patients had endolumenal procedures with 
subsequent requirement of surgical resection. Each patient had no evidence of recurrent 
endolumenal amyloid after 5 to 8 years. Herman et al. reported on 13 cases of 
tracheobronchial amyloid successfully treated with Nd:YAG laser. (Herman et al., 1985) 
Follow up of another patient with CT imaging showed stabilization of the lesions after laser 
resection. (M’Rad et al., 1988) In a series by Diaz-Jimenez three of 11 laser ablations required 
termination because of significant hemorrhage. (Diaz-Jimenez et al., 1999) 
In addition to photoablative strategies, cryotherapy has also been utilized to treat 
tracheobronchial amyloidosis. (Maiwand et al., 2001) Like other endolumenal therapies, 
multiple treatments (21 procedures over an 11 year follow up) over the patient’s disease 
course are often required.  
Rigid bronchoscopy has been utilized to mechanically debulk the amyloid lesions and for 
serial dilation of stenotic airways. In addition, the rigid bronchoscope has been used to help 
with potential bleeding when undergoing biopsy or laser photoablation. Placement of 
silicone stents has been utilized in conjunction with the ablative therapies to help prolong 
the airway stability. (Yang et al., 2003)  
The use of airway stents after dilation may also be considered in select patients. Serial 
therapeutic bronchoscopies are not uncommon. (Gibbaoui et al., 2004) If large mediastinal 
amyloid masses or lymphadenopathy cause central airway obstruction airway stenting is an 
option. As in all benign airways disease it is always preferential to implant a silicone stent. If 
a self expanding metallic stent is the only option, the authors recommend a fully covered 
stent. Operator experience should not be the determinant of the type of stent placed. 
Because of the complex nature of these patients, the high risk of significant bleeding, and the 
potential for repeated procedural requirements, it is recommended that these patients be 
referred to a formally trained interventional pulmonologist or thoracic surgeon with 
significant experience in managing high grade central airway obstruction.  
Localized tracheobronchial amyloidosis can cause post obstructive pneumonia. (Daniels et 
al., 2007) When evidence suggests a post obstructive state, appropriate empiric antibiotics 
should be started. Once bronchoscopic cultures are obtained, a strategy of proper de-
escalation of therapy should be employed based upon the culture results. 
7.3 Radiation therapy  
External beam radiotherapy has been successfully utilized in tracheobronchial amyloidosis 
in a patient believed not to be a candidate for endolumenal therapy due to the diffuse nature 
of the airways disease. (Monroe et al., 2004) A total of 24 Gy was delivered in 12 fractions, 
and colchicine was given as an adjunctive therapy. Improvements were measured by 
sequential pulmonary function testing, radiographic imaging, bronchoscopic evaluation, 
and performance status.  
Kurrus et al. published a case report demonstrating a benefit of external beam radiation (20 
Gy in 10 fractions) in causing local response in a patient with localized tracheobronchial 
disease. (Kurrus et al., 1998) The authors noted decreased thickness of the airway wall and 
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less friable and erythematous airway post radiation on a subsequent bronchoscopy. They 
treated the patient based on the hypothesis that plasma cells that secrete amyloidogenic 
protein are radiosensitive. Other hypotheses proffered include radiation injures cells other 
than plasma cells that may secrete amyloidogenic proteins, and free radicals generated by 
radiation may modify and enhance the degradation of amyloid protein deposits. Combined 
endobronchial and radiation therapy have demonstrated a similar beneficial effect. (Kalra et 
al., 2001). The authors know of no reports utilizing high dose rate brachytherapy for 
endobronchial disease. It stands to reason that this too would be a potentially viable option.  
7.4 Pleural drainage 
Large recurrent pleural effusions in patients with amyloidosis will often require repeated 
thoracenteses followed by pleurodesis. (Berk et al., 2003; Berk et al., 2005) In a case series 
reporting on 35 patients with recurrent amyloid pleural effusions at Boston University, chest 
tubes were placed in 18 patients after a failure of diuresis and intermittent thoracenteses. 
Seven patients had the chest tube removed without chemical pleurodesis because of 
unremitting large volume drainage. Eight patients underwent talc slurry pleurodesis via 
chest tube with symphysis achieved in those with output less than 100 ml/day while in 
those patients with more than 200 ml/day, the pleurodesis failed uniformly. Video-assisted 
thoracoscopic surgery with talc insufflation achieved success in 2 patients, and another 2 
patients had PleurX™ catheters placed for continued intermittent drainage. 
8. Conclusions 
In conclusion, although amyloid in the respiratory tract is not a common occurrence, 
physicians should be aware of the various manifestations. Symptoms of pulmonary 
amyloidosis are very non specific and hence require a high degree of clinical suspicion. The 
workup should include a complete physical examination, pulmonary function testing, 
appropriate clinical imaging followed by biopsies and pathology confirmation of amyloid. 
The treatment strategy needs to be individualized to the particular patient’s clinical status 
and symptomatology, and may range from close observation to locally directed and 
systemic therapeutic options. Airway interventions, including debulking of amyloidomas 
with rigid bronchoscopy, laser photoablation, or airway stents should be performed by an 
experienced interventional pulmonologist or thoracic surgeon. This will help reduce the 
risks of these therapies and allow the most expansive treatment options in a rare condition 
with un-defined best practices. 
Future therapies will focus on strategies that involve preventing formation or propagation 
of insoluble beta-pleated sheets and/or enhance their degradation. Two ubiquitous 
molecules, serum amyloid P (SAP) and heparin sulfate proteoglycan (HSP), promote beta 
pleated sheet formation and inhibition of proteolytic degradation. (Gillmore et al., 2010) 
Drugs that target these molecules may be of interest in the future. 
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